AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib and bortezomib combination
Number of subjects: 11
Study 25986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose level of sorafenib and bortezomib
Number of subjects: 11
Study 25986629 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature of sensor-augmented insulin pump (SAP) therapy
Number of subjects: 0
Study 25986629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25986784 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) at 1 mA for 20 minutes
Number of subjects: 60
Study 25986784 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 25987537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) as an adjunct to standard treatment
Number of subjects: 34
Study 25987537 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 34
Study 25987537 — intervention group
Group type: COMPARATOR
Intervention: Non-SC control group
Number of subjects: 34
Study 25987590 — intervention group
Group type: EXPERIMENTAL
Intervention: Surpass flow diverter
Number of subjects: 20
Study 25987620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, levofloxacin (750 mg) once daily, streptomycin (1 g) once daily
Number of subjects: 16
Study 25987620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloserine (250 mg), p-aminosalicylic acid (PAS) (5.28 g), prothionamide (250 mg) twice daily, pyrazinamide (1,500 mg) once daily, moxifloxacin (400 mg) once daily, kanamycin (1 g) once daily
Number of subjects: 16
Study 25987775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 516
Study 25987791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100000 IU per week for 4 weeks followed by 100000 IU per month in combination with PegIFN/RBV for 12 months.
Number of subjects: 32
Study 25988359 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with clopidogrel
Number of subjects: 1063
Study 25988359 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin with clopidogrel
Number of subjects: 1063
Study 25988359 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH alone
Number of subjects: 1063
Study 25988359 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1063
Study 25989179 — intervention group
Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) powder, dosage of 8 g/d and 14 g/d
Number of subjects: 36
Study 25989179 — intervention group
Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) powder
Number of subjects: 36
Study 25989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 14
Study 25989594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 20
Study 25989594 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20
Study 25989594 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring 12 third- or fourth-generation airways
Number of subjects: 20
Study 25989829 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 400 mg for 8 weeks after switching from bPI or EFV
Number of subjects: 31
Study 25989829 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 31
Study 25989973 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of FSFI during menstruation
Number of subjects: 33
Study 25989973 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of FSFI between menses
Number of subjects: 33
Study 25990577 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 52 mg
Number of subjects: 165
Study 25990577 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 165
Study 25990577 — intervention group
Group type: COMPARATOR
Intervention: Both IUDs
Number of subjects: 165
Study 25991083 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 80 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Number of subjects: 25
Study 25991083 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg q.d. + deleobuvir 600 mg b.i.d. + weight-based ribavirin
Number of subjects: 25
Study 25991462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 88
Study 25991462 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 88
Study 25992287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers measuring MUAC using a colour-banded MUAC strap after minimal training
Number of subjects: 103
Study 25992287 — intervention group
Group type: COMPARATOR
Intervention: Community Health Workers (CHW) following current MUAC protocols
Number of subjects: 103
Study 25992307 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention (microfinance loan, micro-irrigation pump, seeds, fertilizer, training)
Number of subjects: 140
Study 25992307 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention
Number of subjects: 140
Study 25992307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 3759
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus lopinavir/ritonavir
Number of subjects: 3759
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 3759
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatments duration
Number of subjects: 3759
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4
Number of subjects: 3759
Study 25992639 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted viral load at delivery
Number of subjects: 3759
Study 25992656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration training (n = 17)
Number of subjects: 35
Study 25992656 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 35
Study 25993630 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine therapy (single dose and 6-week steady-state trial)
Number of subjects: 3
Study 25993625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application to the sole of the foot
Number of subjects: 21
Study 25993625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application to the calf
Number of subjects: 21
Study 25993625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application to the ankle
Number of subjects: 21
Study 25993984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 106
Study 25994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men
Number of subjects: 720
Study 25994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in women
Number of subjects: 720
Study 25994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men with adjustments for traditional risk factors
Number of subjects: 720
Study 25994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in women with adjustments for traditional risk factors
Number of subjects: 720
Study 25994184 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in men with adjustments for PWV and IMT
Number of subjects: 720
Study 25994356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 81
Study 25994356 — intervention group
Group type: EXPERIMENTAL
Intervention: fatigue visual analogue scale (fVAS)
Number of subjects: 81
Study 25994356 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and depression
Number of subjects: 81
Study 25994356 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity markers (Mayo score for UC, Harvey-Bradshaw index for CD, CRP, faecal calprotectin)
Number of subjects: 81
Study 25994566 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (tertile 3 vs. tertile 1)
Number of subjects: 6542
Study 25994816 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs11668344-G
Number of subjects: 1790
Study 25994816 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs12294104-T
Number of subjects: 1790
Study 25994816 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs10852344-T
Number of subjects: 1790
Study 25994816 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score from 16 variants
Number of subjects: 1790
Study 25995224 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow-infiltrating lymphocytes (MILs)
Number of subjects: 25
Study 25995289 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dietary recalls
Number of subjects: 477
Study 25995313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (325 mg)
Number of subjects: 10213
Study 25995313 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 10213
Study 25996360 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 43
Study 25996360 — intervention group
Group type: COMPARATOR
Intervention: No Total Hip Replacement (non-THR)
Number of subjects: 43
Study 25998039 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI ≤0.90
Number of subjects: 897
Study 25998039 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 897
Study 25998039 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/angiotensin receptor blockers
Number of subjects: 897
Study 25998039 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 897
Study 25998042 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib (various formulations including bisphosphate salt capsules, freebase tablets, and solution formulation)
Number of subjects: 132
Study 25998042 — intervention group
Group type: COMPARATOR
Intervention: Foretinib (solution formulation)
Number of subjects: 132
Study 25998717 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy with the Lokomat® system (Intervention group, IG)
Number of subjects: 30
Study 25998717 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative physiotherapy (Control group, CG)
Number of subjects: 30
Study 25999106 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR with a pre-specified cut-off of 0.89
Number of subjects: 598
Study 25999106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid iFR-FFR approach
Number of subjects: 598
Study 25999106 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR outside of treatment (≤0.85) and deferral (≥0.94) values
Number of subjects: 598
Study 25999107 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Distal-to-Aortic Pressure Ratio
Number of subjects: 0
Study 25999107 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25999108 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve System implanted at an optimal depth (≤6 mm below the aortic annulus)
Number of subjects: 194
Study 25999108 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block
Number of subjects: 194
Study 25999108 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset first-degree atrioventricular block
Number of subjects: 194
Study 25999108 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new PPI
Number of subjects: 194
Study 25999183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg pretreatment
Number of subjects: 173
Study 25999183 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF without ASA
Number of subjects: 173
Study 25999183 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF with ASA
Number of subjects: 173
Study 25999183 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow dose titration DMF
Number of subjects: 173
Study 25999183 — intervention group
Group type: COMPARATOR
Intervention: Placebo ASA
Number of subjects: 173
Study 25999292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 267
Study 25999292 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 267
Study 25999401 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of AF
Number of subjects: 9935
Study 25999401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 9935
Study 25999401 — intervention group
Group type: COMPARATOR
Intervention: Adjusted risk of death
Number of subjects: 9935
Study 25999401 — intervention group
Group type: COMPARATOR
Intervention: Adjusted risk of cardiovascular hospitalization
Number of subjects: 9935
Study 25999401 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident AF ablation
Number of subjects: 9935
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg (cohort 1)
Number of subjects: 15
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg (cohorts 2 and 3)
Number of subjects: 15
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH2101 0.2 mg/kg (cohort 1)
Number of subjects: 15
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH2101 1 mg/kg (cohort 2)
Number of subjects: 15
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH2101 2 mg/kg (cohort 3)
Number of subjects: 15
Study 25999435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lenalidomide and IPH2101
Number of subjects: 15
Study 25999444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib, specific dosage and duration not available
Number of subjects: 0
Study 26000222 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0
Study 26000503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis in maternal blood samples
Number of subjects: 50
Study 26000503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis at ultrasonographic gestational ages of 8 weeks or greater
Number of subjects: 50
Study 26001109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3209
Study 26001109 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 3209
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: Daytime surgery
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: Evening surgery
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: Night-time surgery
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: Evening surgery (adjusted)
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: Night-time surgery (adjusted)
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: ICU admission rate during daytime
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: ICU admission rate during evening
Number of subjects: 11290
Study 26001104 — intervention group
Group type: COMPARATOR
Intervention: ICU admission rate during night-time
Number of subjects: 11290
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical interlead distance (EID) >84 ms
Number of subjects: 216
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal corrected interlead distance (HCID) >90 mm
Number of subjects: 216
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: EID <84 ms and HCID <90 mm
Number of subjects: 216
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical composite score improvement after 12 months
Number of subjects: 216
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: EID cutoff value
Number of subjects: 216
Study 26001509 — intervention group
Group type: EXPERIMENTAL
Intervention: HCID cutoff value
Number of subjects: 216
Study 26001635 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 325
Study 26001635 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 325
Study 26001791 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-color flow cytometry
Number of subjects: 122
Study 26001791 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 122
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII + antifibrinolytics
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII + platelets ± antifibrinolytics
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets ± antifibrinolytics
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytics alone
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 829
Study 26001793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to treatments including recombinant activated factor VII
Number of subjects: 829
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa
Number of subjects: 96
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+antifibrinolytics
Number of subjects: 96
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets±antifibrinolytics
Number of subjects: 96
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+platelets±antifibrinolytics
Number of subjects: 96
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa, with or without platelets (±antifibrinolytics)
Number of subjects: 96
Study 26001792 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa+platelets+antifibrinolytics
Number of subjects: 96
Study 26002091 — intervention group
Group type: EXPERIMENTAL
Intervention: Test intervention (toothpaste and toothbrushes mailed every three months, education and social support via postcards, recorded messages, and optional helpline)
Number of subjects: 21743
Study 26002091 — intervention group
Group type: COMPARATOR
Intervention: Active control (kit of supplies mailed, no additional instructional information or telephone support)
Number of subjects: 21743
Study 26002091 — intervention group
Group type: COMPARATOR
Intervention: Passive control (waiting list)
Number of subjects: 21743
Study 26002711 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategies other than direct clipping
Number of subjects: 19
Study 26002753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 61
Study 26002835 — intervention group
Group type: EXPERIMENTAL
Intervention: eA1c using MyStar Extra blood glucose meter
Number of subjects: 133
Study 26003007 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 60 mg/d continuously, Cisplatin 75 mg/m², Pemetrexed 500 mg/m² once every 21 days for up to 6 cycles.
Number of subjects: 9
Study 26003997 — intervention group
Group type: EXPERIMENTAL
Intervention: Black obese adolescent females
Number of subjects: 61
Study 26003997 — intervention group
Group type: COMPARATOR
Intervention: White obese adolescent females
Number of subjects: 61
Study 26006067 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 iv every 21 days and eribulin 1.4 mg/m2 on day 1 and day 8 every 21 days for four cycles
Number of subjects: 30
Study 26006114 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with NAFLD
Number of subjects: 49
Study 26006114 — intervention group
Group type: EXPERIMENTAL
Intervention: ob/ob mice
Number of subjects: 49
Study 26006114 — intervention group
Group type: EXPERIMENTAL
Intervention: ob/ob mice treated with aT
Number of subjects: 49
Study 26006717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of internal jugular vein
Number of subjects: 311
Study 26006717 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 311
Study 26006717 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparing top and bottom tertiles of JVD ratio
Number of subjects: 311
Study 26007682 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) applied at community and primary health centres.
Number of subjects: 0
Study 26007682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis (CEA) and qualitative thematic analysis alongside the trial.
Number of subjects: 0
Study 26007682 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured questionnaires for data collection.
Number of subjects: 0
Study 26007682 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups (FGs) with pregnant women, household male-decision makers, care providers, and district level health decision makers.
Number of subjects: 0
Study 26009269 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib 175mg orally daily
Number of subjects: 21
Study 26009994 — intervention group
Group type: EXPERIMENTAL
Intervention: siG12D-LODER™ (0.025mg, 0.75mg, and 3.0mg) plus Gemcitabine
Number of subjects: 15
Study 26009994 — intervention group
Group type: EXPERIMENTAL
Intervention: siG12D-LODER™ plus chemotherapy
Number of subjects: 15
Study 26010254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat dietary intervention
Number of subjects: 249
Study 26010254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate dietary intervention
Number of subjects: 249
Study 26010254 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 249
Study 26010298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory cleft opacification quantified using 3D volumetric analysis and SIT-40 assessment before and after sinus surgery.
Number of subjects: 199
Study 26010298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund-Mackay CT scoring for sinus opacification.
Number of subjects: 199